How many insider trades does FilingIQ track for SANA?

FilingIQ tracks 151 Form 4 insider transactions for SANA (Sana Biotechnology, Inc.), covering filings from Feb 3, 2021 onwards. 22 of those were filed in the last 90 days.

Are SANA insiders net buyers or net sellers?

Across the full Form 4 history for SANA, 11 transactions (7%) were open-market purchases and 31 (21%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does SANA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is SANA in?

Sana Biotechnology, Inc. (SANA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.13B.

SANA insider trading

NasdaqGS Healthcare

Sana Biotechnology, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

151

Last 90 days

Buys / sells

7% / 21%

Market cap

$1.13B

About Sana Biotechnology, Inc.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin's lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Company website: www.sana.com

SANA insider activity at a glance

FilingIQ has scored 151 insider transactions for SANA since Feb 3, 2021. The most recent filing in our index is dated Apr 6, 2026.

Across the full history, 11 open-market purchases and 31 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on SANA insider trades is 51.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live SANA trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for SANA?: FilingIQ tracks 151 Form 4 insider transactions for SANA (Sana Biotechnology, Inc.), covering filings from Feb 3, 2021 onwards. 22 of those were filed in the last 90 days.
Are SANA insiders net buyers or net sellers?: Across the full Form 4 history for SANA, 11 transactions (7%) were open-market purchases and 31 (21%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does SANA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is SANA in?: Sana Biotechnology, Inc. (SANA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.13B.

Methodology & sources

Every SANA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.